RBR-4b32m3
Recruiting
未知
Motors Effects in Parkinson's Disease by the action of 5-HT2a/c antagonistic drug mediated by ELF2-alpha factor phosphorylation pathway in humans. A Double-Blind Randomized Controlled Trial.
niversidade Federal da Integração Latino-Americana do Brasil (UNILA).0 sitesAugust 26, 2020
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversidade Federal da Integração Latino-Americana do Brasil (UNILA).
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Individuals with PD clinically diagnosed according to the London Brain Bank criteria. Individuals who voluntarily agree with the procedures and information of the Free and Informed Consent Form. Have cognitive function that allows the understanding of past information by the researcher during the tests (Mini Mental State Examination). Do not present conditions that hinder or impede the movement of the upper limbs, such as: surgeries in the last 12 months; musculotendinosus injuries; fractures; use of prostheses or prostheses; other associated neurological or neurodegenerative conditions; etc. Individuals classified in phase 3 of the Hoeh and Yahr scale.
Exclusion Criteria
- •Withdrawal from participation in the research. Incomplete completion of the instruments. Individuals with treatment abandonment. Patients with symptoms of parkinsonism induced by exogenous intoxication, infectious, vascular, metabolic, genetic causes, other degenerative diseases or by drugs \- such as dopaminergic receptor blockers, anticholinesterases, anticonvulsants, antiarrhythmics, reserpine, tetrabenazine, alfamethyldopa, lithium and fluoxetine. Patients who do not want to stop using monoamine oxidase (MAO) inhibitor drugs. Patients who do not interrupt the use of monoamine oxity (MAO) inhibitor drugs in 15 days before the start of the survey. MAO inhibitors are considered, among others, the following medications: Phenelzine; Iproniazid; Isocarboxazide; Harmalina; Nialamide; Pargyline; Selegiline; Toloxatone; Tranilcipromina. Patients who need to use the linezolid antibiotic, digoxin or phenytoin during the experiment. Diabetic patients or patients with other chronic diseases. Individuals with cardiac disorders or in the recovery phase of an acute myocardial infarction . Patients with reports of psychological disorders such as schizophrenia or bipolar disorder. Patients with renal or hepatic impairment. Pregnant or lactating patients. Patients who have changed the treatment of PD in the past 03 months.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Pain, cognition and motor behavior in Parkinson's diseaseParkinson's disease1002803710009841NL-OMON44397Vrije Universiteit110
Completed
Not Applicable
Quantification of Parkinson*s Disease motor symptoms using the PowerGloveParkinson's diseasePD10028037NL-OMON40878Academisch Medisch Centrum35
Recruiting
Not Applicable
Impairments of Parkinson's disease patients with deep brain stimulation: Development and validation of a self-report and proxy-rated questionnaireG20Parkinson diseaseDRKS00004770Deutsche Parkinson Vereinigung (dPV)1,500
Completed
Not Applicable
Compensatory Mechanisms in Parkinson Disease (PD)Parkinson's DiseaseNCT02038608Hospices Civils de Lyon49
Not yet recruiting
Phase 3
Evaluation of association of Parkinsons Disease symptoms with urinary vesicles(exsomes).Health Condition 1: G20- Parkinsons diseaseCTRI/2021/06/033946DrDinesh Upadhya